| 6END: reference: Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors., Numao S, Hasler F, Laguerre C, Srinivas H, Wack N, Jager P, Schmid A, Osmont A, Rothlisberger P, Houguenade J, Bergsdorf C, Dawson J, Carte N, Hofmann A, Markert C, Hardaker L, Billich A, Wolf RM, Penno CA, Bollbuck B, Miltz W, Rohn TA, Sci Rep. 2017 Oct 19;7(1):13591. doi: 10.1038/s41598-017-13490-1. PMID: 29051536 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).